Parkinson's disease and osteoporosis

Autor: Marten Munneke, Harald J. J. Verhaar, Frederiek van den Bos, Monique M. Samson, Bastiaan R. Bloem, Arlène D. Speelman
Rok vydání: 2013
Předmět:
Male
Aging
medicine.medical_specialty
Bone density
Quality of nursing and allied health care [NCEBP 6]
Osteoporosis
Functional Neurogenomics Human Movement & Fatigue [DCN 2]
Risk Assessment
Gastroenterology
Bone and Bones
vitamin D deficiency
Bone remodeling
Sex Factors
Bone Density
Risk Factors
Internal medicine
medicine
Vitamin D and neurology
DCN MP - Plasticity and memory NCEBP 4 - Quality of hospital and integrated care
Humans
Vitamin D
Aged
Bone mineral
Bone Density Conservation Agents
business.industry
Parkinsonism
Age Factors
Parkinson Disease
General Medicine
Middle Aged
Vitamin D Deficiency
medicine.disease
Osteopenia
Human Movement & Fatigue [DCN MP - Plasticity and memory NCEBP 10]
Treatment Outcome
Endocrinology
Dietary Supplements
Accidental Falls
Calcium
Female
Bone Remodeling
Geriatrics and Gerontology
business
Risk Reduction Behavior
Osteoporotic Fractures
Zdroj: Age and Ageing, 42, 156-62
Age and Ageing, 42, 2, pp. 156-62
ISSN: 0002-0729
Popis: Item does not contain fulltext BACKGROUND: patients with Parkinson's disease (PD) have a high risk of sustaining osteoporotic fractures as a result of falls and reduced bone mass. OBJECTIVE: to summarise the underlying pathophysiological mechanisms of bone loss in PD by reviewing the available literature. METHODS: a Medline search was performed for articles published between January 1975 and January 2011, using the keywords 'bone mineral density', 'bone loss', 'bone metabolism', 'osteoporosis', 'osteopenia', 'Parkinson's disease' and 'Parkinsonism'. RESULTS: PD patients have a lower bone mineral density (BMD) than age-matched controls. Bone loss in PD is multifactorial, resulting from immobility, decreased muscle strength, and low body weight. Vitamin D deficiency is also important, not only because it reduces BMD, but also because cell function in the substantia nigra depends on vitamin D. Lastly, hyperhomocysteinaemia, an independent risk factor for osteoporosis, is common in PD, due to levodopa use, as well as vitamin B12 and folic acid deficiency. A few studies have demonstrated that treatment with bisphosphonates, vitamin D and calcium can increase BMD and reduce fractures in PD patients. CONCLUSION: bone loss in PD is multifactorial. It is clinically important because of the concomitant risk of fractures. Screening for osteoporosis should be considered more often, and therapeutic interventions should be initiated.
Databáze: OpenAIRE